Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 1
1987 10
1988 18
1989 17
1990 17
1991 20
1992 29
1993 30
1994 26
1995 28
1996 27
1997 19
1998 27
1999 36
2000 34
2001 32
2002 22
2003 38
2004 29
2005 33
2006 38
2007 43
2008 54
2009 41
2010 49
2011 33
2012 47
2013 54
2014 88
2015 115
2016 114
2017 159
2018 190
2019 207
2020 236
2021 208
2022 188
2023 52
Text availability
Article attribute
Article type
Publication date

Search Results

2,169 results
Results by year
Filters applied: . Clear all
Page 1
Glioblastoma.
Wirsching HG, Galanis E, Weller M. Wirsching HG, et al. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. Handb Clin Neurol. 2016. PMID: 26948367 Review.
Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endothelial proliferation, resulting in the assignment of grade IV, the highest grade in the World Health Organization (WHO) classification of …
Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endo …
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Vogelbaum MA, et al. J Clin Oncol. 2022 Feb 10;40(5):492-516. doi: 10.1200/JCO.21.02314. Epub 2021 Dec 21. J Clin Oncol. 2022. PMID: 34932393
PURPOSE: To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. ...RECOMMENDATIONS: Surgery is a reasonable option for pati …
PURPOSE: To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS: AS …
Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?
Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Brown PD, et al. J Clin Oncol. 2018 Feb 10;36(5):483-491. doi: 10.1200/JCO.2017.75.9589. Epub 2017 Dec 22. J Clin Oncol. 2018. PMID: 29272161 Free PMC article. Review.
An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with b …
An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone …
Imaging of intratumoral heterogeneity in high-grade glioma.
Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Hu LS, et al. Cancer Lett. 2020 May 1;477:97-106. doi: 10.1016/j.canlet.2020.02.025. Epub 2020 Feb 27. Cancer Lett. 2020. PMID: 32112907 Free PMC article. Review.
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.
Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, Eaton BR, Hattangadi-Gluth JA, Kim MM, Kotecha R, Kraemer L, Li J, Nagpal S, Rusthoven CG, Suh JH, Tomé WA, Wang TJC, Zimmer AS, Ziu M, Brown PD. Gondi V, et al. Pract Radiat Oncol. 2022 Jul-Aug;12(4):265-282. doi: 10.1016/j.prro.2022.02.003. Epub 2022 May 6. Pract Radiat Oncol. 2022. PMID: 35534352
Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for all tumors causing mass effect and/or that are greater than 4 cm. For patients with symptomatic brain metastases, upfront local therapy is strongly recomme …
Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for all tumors causing mas …
Sex-Specific Differences in Glioblastoma.
Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Carrano A, et al. Cells. 2021 Jul 14;10(7):1783. doi: 10.3390/cells10071783. Cells. 2021. PMID: 34359952 Free PMC article. Review.
Sex differences have been well identified in many brain tumors. Even though glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has the worst outcome, well-established differences between men and women are limited to incidence an …
Sex differences have been well identified in many brain tumors. Even though glioblastoma (GBM) is the most common primary mali …
Neuro-oncologic Emergencies.
Suarez-Meade P, Marenco-Hillembrand L, Sherman WJ. Suarez-Meade P, et al. Curr Oncol Rep. 2022 Aug;24(8):975-984. doi: 10.1007/s11912-022-01259-3. Epub 2022 Mar 30. Curr Oncol Rep. 2022. PMID: 35353348 Review.
PURPOSE OF REVIEW: Patients with brain and spine tumors are at high risk of presenting cancer-related complications at disease presentation or during active treatment and are usually related to the type and location of the lesion. ...Brain tumor patients are …
PURPOSE OF REVIEW: Patients with brain and spine tumors are at high risk of presenting cancer-related complications at disease …
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U. Lassaletta A, et al. J Clin Oncol. 2017 Sep 1;35(25):2934-2941. doi: 10.1200/JCO.2016.71.8726. Epub 2017 Jul 20. J Clin Oncol. 2017. PMID: 28727518 Free PMC article.
Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). ...
Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods A combined clinical and ge …
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. Ramos-Fresnedo A, et al. J Neurooncol. 2022 Mar;157(1):177-185. doi: 10.1007/s11060-022-03960-6. Epub 2022 Feb 17. J Neurooncol. 2022. PMID: 35175545
The 2021 WHO classification now considers IDH-wildtype diffuse astrocytic tumors without the histological features of glioblastoma (that would have otherwise been classified as grade 2 or 3) as molecular GBM (molGBM, WHO grade 4) if they harbor any of the following molecul …
The 2021 WHO classification now considers IDH-wildtype diffuse astrocytic tumors without the histological features of glioblastoma (t …
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Sarkaria JN, et al. Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Neuro Oncol. 2018. PMID: 29016900 Free PMC article. Review.
The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The ac …
The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of …
2,169 results